Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells from PD patients and controls.

Background: Alpha-synuclein (SNCA) oligomers are believed to be the major neurotoxic agents in neurodegenerative process in Parkinson’s disease (PD). SNCA gene expression has been shown to be regulated by DNA SNCA-intron1 methylation status. DNMT1 is a DNA methylation enzyme predominantly involved in the maintenance of DNA methylation during cell division.

Method: This study included 43 PD patients (mean age 66.24±7.05 years) and 47 healthy individuals (mean age of 60.09±7.21 years) as the control group. All subjects were residents from the North-Western region of Russia and provided informed consent. The study was approved by the local ethics committee. CD45+ cells were isolated from peripheral blood by density gradient centrifugation followed by magnetic separation of a homogeneous fraction of CD45+ cells using CD45+ MicroBeads and MACS Columns. The level of DNMT1 and global DNA methylation were estimated by ELISA and ELISA-like colorimetric methods, respectively. Statistical analysis was performed using SPSS 21.0.

Results: The level of DNMT1 in CD45+ blood cells was decreased in PD patients compared to control (p<0.001). No differences between PD patients and controls in global DNA methylation were found (p=0.34).

Conclusion: Our data suggest the involvement of DNMT1in PD pathogenesis.

References: This research has been supported by the Ministry of Education and Science of the Russian Federation (grant number №121060200125-2).

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/dnmt1-level-and-global-dna-methylation-in-cd45-blood-cells-in-parkinsons-disease/